@article{df1fc0101ff944119759540ad1600dfe,
title = "Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia",
abstract = "The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease. FH is among the most commonly occurring congenital metabolic disorders. FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated, particularly among children. Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD.",
keywords = "Apheresis, Cascade screening, Familial hypercholesterolemia, Heterozygote, Heterozygous, Homozygote, Homozygous, LDL receptor",
author = "Goldberg, {Anne C.} and Hopkins, {Paul N.} and Toth, {Peter P.} and Ballantyne, {Christie M.} and Rader, {Daniel J.} and Robinson, {Jennifer G.} and Daniels, {Stephen R.} and Gidding, {Samuel S.} and {De Ferranti}, {Sarah D.} and Ito, {Matthew K.} and McGowan, {Mary P.} and Moriarty, {Patrick M.} and Cromwell, {William C.} and Ross, {Joyce L.} and Ziajka, {Paul E.}",
note = "Funding Information: Dr. de Ferranti has received research grants from GlaxoSmithKline. Funding Information: Dr. Gidding has received honoraria related to consulting from Merck & Co. Dr. Gidding has received research grants from GlaxoSmithKline. Funding Information: Dr. Goldberg has received honoraria related to consulting from Roche/Genentech, ISIS-Genzyme and Merck & Co. Dr. Goldberg has received research grants from Amarin, Abbott Laboratories, GlaxoSmithKline, ISIS-Genzyme Corporation, Merck & Co., Novartis, and Regeneron. Funding Information: Dr. Hopkins has received honoraria related to speaking from Abbott Laboratories, AstraZeneca, and Merck & Co. Dr. Hopkins has received research grants from Takeda Pharmaceuticals. Funding Information: Dr. Robinson has received research grants from Abbott Laboratories, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Hoffman LaRoche, Merck & Co., Merck Schering Plough, and Spirocor. Funding Information: Dr. Ziajka has received honoraria related to speaking from Abbott Laboratories, AstraZeneca and Merck & Co. Dr. Ziajka has received research grants from Genzyme Corporation.",
year = "2011",
month = may,
doi = "10.1016/j.jacl.2011.03.001",
language = "English",
volume = "5",
pages = "133--140",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
number = "3",
}